* Newstin.co.uk is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.co.uk and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.co.uk is for sale! *
Full Coverage

Skyepharma PLC Announces Research Update

pharmiweb.co.uk
03-Jul-2008
        
Story Timeline:  96 days

More News related to Press Releases SkyePharma Announces Third FlutiformTM Phase III Efficacy Study Meets Primary Endpoints and Completes Original Core Clinical Trial Programme LONDON, UK, 3 July, 2008 - SkyePharma PLC (LSE: SKP) today announces that its third Phase III efficacy study evaluating FlutiformTM for the treatment of mild to moderate asthma in adolescent and adult patients has met its primary endpoints. This is the third of several clinical efficacy studies being carried out in preparation for regulatory filing and completes the original core clinical trial programme. The study (SKY2028-3-001) was conducted in centres across North America and Europe. The full analysis set includes a total of 475 patients. The study was a randomised, double-blind, placebo- controlled, parallel group, stratified, multi-centre,... [read full story]                    

Add Comment
Latest article on this story:

Skyepharma PLC Announces Research Update

 redorbit.com 03-Jul-2008
First article on this story:

Skyepharma PLC: Skyepharma PLC Announces Research Update

 marketwire.com 03-Jul-2008
Selected publications with coverage of this story:
redorbit.com marketwire.com earthtimes.org newsblaze.com pharmiweb.co.uk
RELATED
Found 2 documents:

Skyepharma PLC Announces Research Update

earthtimes.org
03-Jul-2008
        

LONDON -- 07/03/08 -- SkyePharma Announces Third FlutiformTM Phase III Efficacy Study Meets Primary Endpoints and Completes Original Core Clinical Trial Programme LONDON, UK, 3 July, 2008 - SkyePharma PLC (LSE: SKP) today...

                   

Skyepharma PLC: Skyepharma PLC Announces Research Update

marketwire.com
03-Jul-2008
        

LONDON--(Marketwire - In a top line analysis of key results, the levels of improvement in FEV1 (forced expiratory volume in the first second), the primary endpoint in the active treatment arms, showed statistically significant...